Singapore’s MerLion Sees Positive Results For Phase I Intravenous Finafloxacin Trial
This article was originally published in PharmAsia News
Executive Summary
Singapore’s MerLion pushes ahead with its finafloxacin anti-bacterial candidate, successfully completing Phase I trials of an intravenous version.